Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca743 enrolled

Overview

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

Study Type

OBSERVATIONAL

Enrollment

743

Conditions

Chronic Obstructive Pulmonary Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * non pregnant female * COPD with persistent symptoms in spite of regular bronchodilator therapy * Naive or fixed combination treated patients including patients already on Symbicort Turbuhaler Exclusion Criteria: * Hypersensitivity to budesonide, formoterol or inhaled lactose

Outcomes

Primary Outcomes

Reduction in overall Clinical COPD Questionnaire (CCQ) score

Time frame: 12 weeks

Secondary Outcomes

Patient satisfaction

Time frame: 12 weeks

Physicians' global clinical impression of the treatment

Time frame: 12 weeks

Evaluation of smoking habits

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.